Germany's New Robotic Heartbeat: Fürth Pioneers Arrhythmia Treatment

FÜRTH, GERMANY – February 09, 2026 – A new era in cardiac care has begun in Germany as Klinikum Fürth today announced the launch of a pioneering robotic electrophysiology program. The hospital has become the first in the nation to adopt the Genesis Robotic Magnetic Navigation (RMN) system from Stereotaxis, a cutting-edge technology designed to treat heart rhythm disorders with unprecedented precision and safety. The first patients at the clinic have already been successfully treated for a range of arrhythmias using the new system.

This move positions Klinikum Fürth, a respected regional medical center, at the forefront of cardiac innovation in Europe. The adoption of the Genesis system addresses a growing health concern in Germany, where atrial fibrillation, the most common type of arrhythmia, affects an estimated 1% to 2.5% of the population and can lead to severe complications like stroke and heart failure if left untreated.

A Leader in Cardiac Care Elevates Its Practice

For Klinikum Fürth, the integration of robotics is a significant enhancement to an already distinguished cardiology department. The clinic’s electrophysiology section, led by Dr. Laura Vitali-Serdoz, is a certified Atrial Fibrillation Ablation Center by the German Society of Cardiology, a testament to its established expertise in treating heart rhythm disorders. This new technology builds upon that foundation, offering physicians a powerful new tool.

“We are proud to be the first in our region to offer this cutting-edge robotic technology and look forward to continuing to use the system to treat patients suffering from heart rhythm disorders,” said Dr. Laura Vitali-Serdoz, Head of the Rhythmology & Invasive Electrophysiology at Klinikum Fürth.

Her colleague, Dr. Dirk Bastian, Deputy Head of the department, emphasized the tangible benefits for both physicians and patients. “The precision and stability offered by Robotic Magnetic Navigation allows us to successfully treat even the most complex arrhythmias with confidence, which is a major benefit for our team and more importantly for our patients,” he stated. “The technology is also minimizing the need for fluoroscopic confirmation and thereby reducing radiation exposure.”

This reduction in radiation is a critical advancement. Conventional cardiac ablation procedures rely heavily on X-ray imaging, exposing both patients and medical staff to radiation. By enhancing precision and stability, the Genesis system reduces the need for this imaging, creating a safer environment in the electrophysiology lab.

How Robotic Magnetic Navigation Redefines Treatment

The Genesis RMN system represents a fundamental shift away from manual catheter manipulation. In a traditional ablation procedure, a physician manually pushes and turns a catheter from its handle to navigate it through blood vessels to the heart. This technique requires immense skill and can be physically demanding, with the catheter’s stability inside the heart subject to fluctuations.

In contrast, the Stereotaxis system uses two externally placed magnets to create a precise magnetic field around the patient. This field guides the soft, flexible tip of a magnetic catheter with 1mm/1° precision. The physician operates the system from a control room, using a computer interface to steer the catheter tip directly to the target tissue inside the heart. This method offers several key advantages:

• Unmatched Precision: The robotic control allows for millimeter-level accuracy, enabling physicians to create more effective and durable lesions to stop the irregular electrical signals causing the arrhythmia.
• Enhanced Stability: The soft catheter is held in place by the magnetic field, ensuring stable contact with the heart wall—a critical factor for successful ablation that can be difficult to achieve manually.
• Safety: The flexible catheter is less likely to cause trauma to delicate heart tissue compared to stiffer manual catheters.
• Access to Complex Anatomy: The system's ability to navigate tortuous pathways allows physicians to treat patients with complex anatomies or arrhythmias that were previously considered too challenging for a minimally invasive approach.

This technology has been used to treat over 150,000 patients globally, but its arrival at Klinikum Fürth marks a significant milestone for its adoption in the robust German healthcare market.

Stereotaxis's Strategic Expansion into a Key European Market

For St. Louis-based Stereotaxis (NYSE: STXS), the partnership with Klinikum Fürth is a strategic victory and a key part of its European expansion. Germany has one of the highest prevalence rates of atrial fibrillation in Europe, representing a substantial market for advanced cardiac rhythm management technologies. Securing the first German installation of the Genesis system, which received its European clearance in 2020, demonstrates the company's growing traction.

“We are proud to partner with Klinikum Fürth to expand access to minimally invasive arrhythmia care in Germany,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to supporting their successful and impactful robotic heart rhythm practice.”

While Stereotaxis is not yet profitable, reporting a net loss in 2024, the company maintains a strong balance sheet with significant cash reserves and no debt. Analysts are optimistic about its growth trajectory, forecasting annual revenue growth near 30% and pointing to a backlog of system orders exceeding $10 million. The company's innovation pipeline remains active, with recent FDA approvals for its semi-mobile GenesisX system and a new MAGiC Ablation Catheter, which are expected to further drive adoption and recurring revenue streams.

The launch at Klinikum Fürth validates the company's long-term strategy of developing a comprehensive ecosystem of robotic technology and disposables that improves patient outcomes and enhances workflow in the interventional lab. As more hospitals seek to treat an aging population with increasingly complex cardiac conditions, the demand for technologies that offer superior precision, safety, and the ability to handle challenging cases is expected to grow, placing Stereotaxis and its partners at the center of a major shift in cardiovascular medicine.